Fairvalue-Calculator Fairvalue-Calculator
EN DE

Daihan Pharmaceutical Co (023910) Fair Value & Analysis

Healthcare · KR · Market cap 156B KRW

Price24,700 KRW
Fair Value56,706 KRW
Upside+129.6%
Quality95/100
Evidence: High Range 39,694 KRW – 73,718 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Daihan Pharmaceutical Co (023910) currently trades at 24,700 KRW, while our model-based Fair Value estimate is 56,706 KRW — implying the stock looks roughly 129.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% United Therapeutics Corporation (U2TH34) -79%

Frequently asked questions

Is Daihan Pharmaceutical Co (023910) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 56,706 KRW versus a price of 24,700 KRW — about +130% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 023910?
Our 21-model fair value for Daihan Pharmaceutical Co is 56,706 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 24,700 KRW.
What is the quality score of 023910?
Daihan Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.